Этамзилат

Quick links

Choose a section

Quick links to important sections

Advertisements

Этамзилат

Advertisements
Advertisements

Treatment option: Crush Injury

Advertisements

Overview of Этамзилат

Property Description
Active ingredient Etamsylate (Ethamsylate)
Form Solution for injection, Tablet
Pharmacological class Antihemorrhagic Agent / Hemostatic Drug
Common purpose Control of small vessel blood loss
Origin Synthetic

Этамзилат (Etamsylate) is a synthetic small molecule compound recognized as an antihemorrhagic agent and a hemostatic drug. It is categorized under the code B02BX01 (other systemic hemostatics) in the WHO ATC Classification. Pharmacological studies have supported its primary action in protecting the microvasculature, which is a distinctive characteristic of this compound compared to agents that primarily modulate coagulation cascade factors.

Composition and Available Forms of Этамзилат

The active substance, Etamsylate, is chemically defined as diethylamine 2,5-dihydroxybenzenesulfonate and is supplied as a single-ingredient product. Its core function focuses on angioprotection by working directly to reinforce the structural integrity of the capillary walls. Etamsylate helps stabilize the vessel structure, contributing to the reduction of bleeding time associated with microvascular damage. This establishes its role in supporting the vascular system itself.

Этамзилат is commonly available in two systemic forms: a sterile solution for injection intended for parenteral administration, and an oral tablet form, facilitating systemic delivery.

What is the General Purpose of Этамзилат?

The general purpose of Этамзилат is to promote the control of blood loss by increasing capillary resistance and reducing vessel fragility. For instance, it is typically used in scenarios where fine vessel fragility is the core concern. The medicine is known to enhance the natural ability of platelets to adhere to the site of vessel injury. This action aids the body’s non-specific response to hemorrhage by reinforcing the smallest blood vessels.

Advertisements

What side effects are possible with Этамзилат?

Possible Side Effects and Safety Information

The safety profile for Etamsylate is formally categorized by regulatory authorities to distinguish between expected reactions and rare, serious events. Adverse reactions are classified according to frequency and the body systems they affect.

Commonly Documented Adverse Reactions

Adverse reactions classified as Common (affecting 1 to 10 users in 100, according to the SmPC frequency framework) typically involve mild, non-serious events, including headache, nausea, diarrhea, abdominal discomfort, rash, and general weakness (asthenia). These effects are documented under system-organ classes such as Gastrointestinal Disorders, Nervous System Disorders, and Skin and Subcutaneous Tissue Disorders.

Serious Adverse Reactions and Constraints

Very Rare and serious reactions, though infrequent, are listed in regulatory documents and include severe hematological disorders such as agranulocytosis, neutropenia, and thrombocytopenia, as well as the risk of thromboembolism (blood clot formation) and severe hypersensitivity reactions, including anaphylactic shock. The official labeling establishes absolute safety restrictions, or contraindications, that prohibit the use of Etamsylate in individuals with Acute Porphyria, a prior history of thromboembolism, or known hypersensitivity to the drug. The risk of hypotension is also noted upon rapid intravenous administration.

Population-Specific Safety Notes

Safety data is limited for certain groups. Use is generally not recommended during pregnancy unless the potential benefit is determined to outweigh the risk, and it is generally considered inadvisable during lactation. Specific caution is noted for low-birth-weight infants when receiving the injectable formulation.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Information regarding the overdose profile for Etamsylate (Этамзилат) is strictly based on official government regulatory documents. The available prescribing information is highly constrained by a lack of reported clinical cases of acute overexposure.

Documented Overdose Profile

The official Summary of Product Characteristics (SmPC) states that no case of overdose has been reported for Etamsylate. Consequently, regulatory documents do not list any specific symptoms, clinical signs, or severity classifications directly attributable to an overdose. No physiological systems are explicitly identified in the overdose section as being affected, and no specific dose levels are associated with acute risk.

Overdose Entity Regulatory Status
Specific Manifestations None documented; no cases reported.
Specific Antidote No specific antidote is known or mentioned in official labeling.
Required Management Symptomatic and supportive treatment should be initiated.

When to Seek Urgent Medical Attention

Because there are no documented overdose symptoms, immediate medical assistance is required upon the suspicion of overdosage. The official procedural instruction mandated by regulatory authorities for managing suspected overexposure is to start symptomatic and supportive treatment. This standard approach is taken when clinical experience or specific reversal agents are unavailable, ensuring the patient receives necessary medical observation and care.

Advertisements

Therapeutic Uses of Этамзилат

What Этамзилат Treats: Main Uses and Benefits

Этамзилат (Etamsylate) may be part of symptomatic management in conditions associated with capillary fragility and subsequent excessive bleeding, making it relevant across domains where additional symptomatic support is needed. It is considered relevant in conditions involving episodic or fluctuating manifestations, such as those related to periventricular hemorrhage in low birth weight infants.


The medication is commonly used to help manage symptoms related to blood loss that is abnormally high or extended, such as with menorrhagia (heavy menstrual bleeding), dysfunctional uterine bleeding, and episodes of spontaneous bleeding like epistaxis (nosebleeds). It is also applied in clinical settings that involve acute or unstable symptom patterns following invasive procedures, including dental work and delicate surgeries. The therapeutic application may assist with easing the total volume and duration of blood loss, which contributes to easing the overall symptom burden. Furthermore, a specialized use involves supporting the fragile microcirculation in premature and low-birth-weight infants when symptoms linked to organ-specific functional stress are present.

“The medicine is applied in scenarios where additional management of discomfort is required, especially when symptoms create noticeable physiological strain.”

Quick Fact: May help with symptoms related to excessive bleeding

Regulatory References

  1. Health Products Regulatory Authority's Summary of Product Characteristics
Advertisements

Eligibility and Restrictions for Use

The official eligibility profile for Этамзилат (Etamsylate) is defined by mandatory contraindications and specific population restrictions established in government regulatory documents.

Populations Who Must Not Use the Medicine (Contraindicated)

Use of Etamsylate is strictly prohibited for patients with the following conditions:

  • Acute Porphyria
  • Known Hypersensitivity to etamsylate or any of the product’s excipients
  • Bronchial Asthma or confirmed sulphite hypersensitivity

Restricted and Conditional Use

Allowed Populations: The medicine is generally used in adults and is explicitly indicated in regulatory labeling for prophylaxis and treatment in low birth weight infants (under 1.5 Kg).

Organ Function and Special Conditions: Use requires caution in patients with hepatic impairment or renal impairment, as clinical studies to establish use in these specific populations have not been performed.

Physiological States: Use during pregnancy requires caution. Regulatory guidance advises that use while breastfeeding is inadvisable due to the absence of data regarding its presence in breast milk. Additionally, treatment must be discontinued if a treated infant develops a fever.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Этамзилат (Etamsylate) is primarily characterized by constraints related to the injectable formulation, with no formally documented systemic drug-drug interactions related to metabolism.

Documented Administration Constraints (Injection Solution)

The constraints for Etamsylate injection involve chemical and procedural requirements for administration, as detailed in regulatory documents.

Substance / Solution Official Regulatory Constraint
Sodium Bicarbonate solutions The injection solution is incompatible and must not be mixed.
Compound Sodium Lactate solutions The solution is incompatible and must not be mixed.
Thiamine (Vitamin B1) The excipient in the injection solution can cause inactivation of Thiamine.
Dextran infusion Etamsylate injection must be injected first before beginning the Dextran infusion.

Systemic Interaction Profile

The regulatory labeling contains no formal statements regarding the induction or inhibition of Cytochrome P450 enzymes (metabolic interactions) or drug transporters, reflecting a low documented risk of pharmacokinetic interactions that would alter the systemic exposure of other co-administered medicines. Similarly, official documentation includes no explicit restrictions for co-administration with food, alcohol, or herbal products.

Advertisements

Mechanism of Action

The precise mode of action for Etamsylate is not fully known; however, established evidence indicates a dual pharmacodynamic mechanism that modulates the primary hemostasis pathway via direct action on capillary vessels and circulating platelets.

Capillary Wall Stabilization and Resistance

The drug exerts an angioprotective effect by modulating the structure of the smallest blood vessels. It is thought to enhance the synthesis and organization of materials, such as hyaluronic acid, which stabilize the endothelial basement membrane. This action increases the mechanical resistance of the capillaries and lowers their permeability, leading to a core physiological decrease in vascular permeability and increased mechanical resistance.

Modulation of Platelet Adhesion and Plug Formation

The drug modulates primary hemostasis by promoting the capacity of platelets to adhere to the injured vessel wall, partly through enhancing P-selectin function. Simultaneously, it modulates local chemical signals by inhibiting the biosynthesis of Prostacyclin (PGI2), a powerful anti-aggregatory agent. These coordinated actions accelerate the formation of the platelet plug, resulting in accelerated kinetics of primary hemostasis.

Advertisements

Dosage and Administration Information

How to Use Этамзилат

The administration of Etamsylate follows established regimens to ensure precise systemic or local delivery. The medicine is supplied for both oral intake as a tablet and parenterally as a solution for injection, allowing for intravenous (IV) or intramuscular (IM) administration. The solution may also be used for topical application via a saturated swab.

Dosing schedules are context-dependent, generally revolving around individual doses ranging from 250 mg to 500 mg in adults. The frequency is typically prescribed as four times daily for cyclic use during menstruation, or every 4 to 6 hours for managing acute or post-surgical conditions. For use prior to surgery, a dose is administered approximately 1 hour before the procedure.

Administration and Population Adjustments

Specific procedural rules govern the injectable form. If the solution is diluted with 0.9% sodium chloride, it must be used immediately to ensure stability. Furthermore, the injection solution is incompatible with compound sodium lactate and sodium bicarbonate solutions. Due to the potential for a transient fall in blood pressure associated with parenteral administration, monitoring is a recognized procedural consideration.

Dosage is adjusted based on age for certain populations. Neonates, particularly those of low birth weight, follow a weight-based regimen, such as 12.5 mg/kg body weight, administered every 6 hours for a fixed course duration of 4 days. Overall use is characterized by short-term regimens: fixed days for newborns, the duration of menstruation for cyclic use, or a brief course following surgery until the risk is managed.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence


Mechanism of Action and Focus of Study

Studies investigated the medication's actions at the cellular level, particularly its proposed role in supporting capillary wall stability and promoting platelet adhesion. This focus aligns with its studied use as an antihemorrhagic agent intended to limit bleeding from small blood vessels.

Efficacy and Study Outcomes

Clinical trials have evaluated the medication's effect across several conditions where capillary bleeding is a concern:

  • Menorrhagia (Heavy Menstrual Bleeding): Early controlled studies reported on whether the medication was associated with a reduction in mean menstrual blood loss. However, comparative studies, including those using objective blood loss measurement, often noted that the reduction in blood loss was less substantial compared to other medical therapies.
  • Surgical Bleeding: Research has explored the medication's use for managing blood loss during and after certain procedures, such as transurethral resection of the prostate and myomectomy. Some trials reported lower estimated blood loss in treated patients compared to placebo groups.
  • Neonatal Bleeding: Studies have investigated whether the medication affects intraventricular hemorrhage (IVH) in preterm infants. While some data suggested a reduction in IVH in certain subgroups, this finding was not consistently associated with improved neurodevelopmental outcomes or reduced mortality in later childhood.

Safety Profile and Adverse Events in Studies

Clinical trials reported on the frequency of severe adverse events and showed common adverse events included mild nausea and headache. The studies assessed the medication's profile in adult populations, noting that certain patient groups, such as those with severe kidney issues, were typically not enrolled in the initial clinical trials.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Этамзилат (FAQ)

Q: Is it normal to feel a mild headache after taking Этамзилат?

According to official product information, headache is listed as a Common adverse reaction. This frequency category indicates that this effect is reported in 1 to 10 out of every 100 users. This classification suggests it is one of the more frequently observed effects documented in clinical settings.

Q: Is nausea a frequent side effect of the tablet form of Этамзилат?

Official regulatory documents classify nausea as a Common adverse reaction to the medication. This means that, regardless of the form, it is reported in 1 to 10 out of every 100 users. This frequency classification suggests it is a commonly documented, non-serious effect.

Q: Can Этамзилат be used by pregnant or breastfeeding women?

Official guidance states that use during pregnancy requires caution, as its potential benefit is generally considered against the possible risk. Similarly, use while breastfeeding is generally considered inadvisable due to a lack of data on whether the medicine passes into breast milk.

Q: Are there special warnings for elderly patients using Этамзилат?

Caution is officially advised for older adults, and for patients with hepatic impairment (liver issues) or renal impairment (kidney issues). The caution is noted for older adults and individuals with impaired liver or kidney function.

Q: Does taking Этамзилат increase the risk of developing blood clots (thrombosis)?

Regulatory documents list the development of thromboembolism (blood clot formation) as a Very Rare and serious adverse reaction. The medicine is also contraindicated for individuals with a prior history of thromboembolism.

Q: Does the injectable form of Этамзилат work faster than the tablet form?

Official pharmacokinetic data indicates a difference in how quickly the medicine reaches its highest concentration in the blood. Maximum blood levels are achieved in 2–3 minutes following intravenous administration, compared to about one hour following intramuscular injection.

Q: Are there specific instructions for the injection technique for Этамзилат?

The solution is supplied for intravenous (IV) or intramuscular (IM) administration. Regulatory rules state that the solution is incompatible with sodium bicarbonate and compound sodium lactate solutions and must be used immediately if diluted with 0.9% sodium chloride.

Q: Is Этамзилат used to stop bleeding after surgery or trauma?

Official indications for the medication include the prophylaxis and control of haemorrhages from small blood vessels. This use extends to managing bleeding in post-operative conditions and acts by promoting capillary resistance and platelet adhesion.

Q: What is the difference between Этамзилат and tranexamic acid (e.g., Cyklokapron)?

Regulatory information classifies Этамзилат as an Other Systemic Hemostatic agent. It works by increasing capillary resistance and improving platelet adhesion. This mechanism is distinct from antifibrinolytic agents that work by affecting the breakdown of existing blood clots.

Q: Does Этамзилат affect blood pressure, especially the injectable form?

Yes, regulatory documents specifically note the risk of a transient fall in blood pressure (hypotension) upon rapid intravenous administration. Monitoring blood pressure is a recognized procedural consideration when using the injectable form.

Q: Does Этамзилат affect the central nervous system or cause drowsiness?

Official warnings related to its safety profile indicate that the medicine generally does not impair the ability to drive or operate machinery. While headache is listed under Nervous System Disorders, drowsiness is not listed as a common or serious effect.

Q: How long does Этамзилат stay in the body after the last dose?

Pharmacokinetic data suggests that elimination of the substance from the body is generally very rapid. This refers to how quickly the body processes and removes the compound.

Q: Can a patient stop taking Этамзилат abruptly if the bleeding stops?

Treatment regimens are typically based on a fixed course of use, such as for the duration of menstruation or for a set number of days following surgery. Discontinuation is generally done only under the direction of a healthcare professional.

Q: Is Этамзилат a hormonal medication?

No. Official descriptions classify Этамзилат as a synthetic small molecule compound. It belongs to the pharmacological class of Antihemorrhagic Agents and Hemostatic Drugs, and its mechanism of action is focused on blood vessels and platelets.

Q: Is there an established maximum duration for using Этамзилат tablets?

Use of the medicine is officially characterized by short-term regimens. This includes specific periods like the duration of menstruation for cyclic use, or a brief course following surgical procedures.

Q: Can Этамзилат be used to treat internal bleeding not caused by trauma or surgery?

Yes, the medication is indicated for capillary bleeding of different origins (etiology). This includes documented conditions such as hematemesis (blood in vomit), melena (blood in stool), and hematuria (blood in urine).

Q: Is Этамзилат used to treat bleeding disorders like hemophilia?

Этамзилат is classified as an Other Systemic Hemostatic agent. Its primary mechanism acts to strengthen capillary walls and improve platelet adhesion, not by replacing or boosting major coagulation factors, which are the focus of treatment for conditions like hemophilia.

Q: Is there a known interaction between Этамзилат and oral contraceptives?

The official regulatory labeling contains no formal statements regarding the induction or inhibition of metabolic enzymes or drug transporters. This reflects a low documented risk of pharmacokinetic interactions between the medicine and other medications, including oral contraceptives.

Advertisements

How should Этамзилат be stored and disposed of?

Storage and Disposal: Official Regulatory Information

The official profile for Etamsylate mandates strict adherence to environmental controls for the maintenance of product quality and stability.

Storage & Disposal Scope
Labeled storage temperature requirements: Below 25 C (or 15 C to 30 C in some regions).
Light/moisture protection requirements: Must be protected from light and moisture [Source 1.3, 3.1].
Stability after opening/reconstitution (if applicable): For the solution for injection, use within the stated in-use period (e.g., 14 days) after first opening [Source 1.3].
Handling requirements: Do not freeze the product [Source 1.3].
Packaging-related storage rules (if applicable): Store in the original container or outer carton [Source 1.3].
Child-protection storage requirements (if stated): KEEP OUT OF SIGHT AND REACH OF CHILDREN [Source 1.3, 3.1].
Disposal instructions: Dispose of unused or expired medicine according to local regulations [Source 1.3].
Environmental restrictions: Should not be disposed of via wastewater or household waste [Source 1.3].

Official storage and disposal statements:

Regulatory documents specify that Etamsylate must be stored under Controlled Room Temperature and protected from light, moisture, and freezing. The medicine is required to be kept out of the sight and reach of children at all times. Disposal of unused or expired product must follow local regulations for pharmaceutical waste, with explicit instructions to avoid flushing or placing it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Этамзилат found in:

A-Z Index: